Short answer
ArriVent BioPharma, Inc. (AVBP) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$50M
- −58.9% YoY · −15.2% QoQ
- EPS (diluted)
- −$1.05
- −19.3% YoY · −9.4% QoQ
Source: XBRL data from the ArriVent BioPharma, Inc. (AVBP) Q2 2026 10-Q on SEC EDGAR. USD.
ArriVent BioPharma, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY; no products approved or product-sales revenue generated
- Operating margin not applicable; operating loss $52.7M vs $33.6M YoY
- R&D highest program: early-stage programs $13.4M, up $9.8M YoY
- Cash, equivalents and short-term investments $373.1M at June 30, 2026
- ATM issuance $140.0M net proceeds; management expects continued losses and substantially higher R&D spending
Risk Factors
- Newly triggered USPTO ex parte reexamination of RE ’687 Patent following July 2026 request grant
- Patent protection risk from possible narrowing or cancellation of RE ’687 claims
- Intellectual-property proceedings risk from defense costs and management-resource diversion
- Competitive exposure if patent rights no longer cover product candidates or block third-party competition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ArriVent BioPharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.